Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Net Issuance of Debt
Mayne Pharma Group Ltd
Net Issuance of Debt Peer Comparison
Competitive Net Issuance of Debt Analysis
Latest Figures & CAGR of Competitors
Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Mayne Pharma Group Ltd
ASX:MYX
|
Net Issuance of Debt
-AU$375.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Botanix Pharmaceuticals Ltd
ASX:BOT
|
Net Issuance of Debt
-AU$32.4k
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Probiotec Ltd
ASX:PBP
|
Net Issuance of Debt
-AU$5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
6%
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Arovella Therapeutics Ltd
ASX:ALA
|
Net Issuance of Debt
-AU$71.8k
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Mayne Pharma Group Ltd's Net Issuance of Debt?
Net Issuance of Debt
-375.6m
AUD
Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Net Issuance of Debt amounts to -375.6m AUD.